Case report shows guttate psoriasis following tirzepatide use in an adult female, indicating potential adverse effects of GLP-1RAs.
With increasing use of glucagon-like peptide-1 receptor agonists (GLP-1RAs), it is important to recognize possible adverse effects. While most cutaneous GLP-1RAs side effects are related to injection site reactions, there are several documented instances of rare cutaneous effects. We present a novel case of tirzepatide-induced psoriasis resolved with risankizumab-rzaa treatment.
No takes yet. Share an insight, caveat, or question.
Cook et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: